Korean J Gastroenterol.  2011 Sep;58(3):133-138. 10.4166/kjg.2011.58.3.133.

Preclinical Experience in Stem Cell Therapy for Digestive Tract Diseases

• Jeon MS
• Hong SS

• KMID: 1018400
• DOI: http://doi.org/10.4166/kjg.2011.58.3.133

Abstract

Adult stem cells are multipotent and self-renewing cells that contain several functions; i) migration and homing potential: stem cells can migrate to injured and inflamed tissues. ii) differentiation potential: stem cells which migrated to injured tissues can be differentiated into multiple cell types for repairing and regenerating the tissues. iii) immunomodulatory properties: stem cells, especially mesenchymal stem cells can suppress immune system such as inflammation. All those characteristics might be useful for the treatment of the digestive tract diseases which are complex and encompass a broad spectrum of different pathogenesis. Preclinical stem cell therapy showed some promising results, especially in liver failure, pancreatitis, sepsis, and inflammatory bowel disease. If we can understand more about the mechanism of stem cell action, stem cell therapy can become a promising alternative treatment for refractory digestive disease in the near future. In this review, we summarized current preclinical experiences in diseases of the digestive tract using stem cells.

Keyword

Stem cells; Digestive tract; Liver failure; Pancreatitis

MeSH Terms

Adult Stem Cells/cytology/*transplantation
Digestive System Diseases/*therapy
Drug Evaluation, Preclinical
Humans

Figure

• 

  Fig. 1. Scheme of digestive tract diseases investigated in preclinical stem cell therapy. Approximate numbers of published articles are indicated in parentheses.

• 

  Fig. 2. Mechanism for therapeutic effects of mesenchymal stem cells on pancreatitis.25

Reference

References

1. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008; 8:726–736.

2. English K, French A, Wood KJ. Mesenchymal stromal cells: facili-tators of successful transplantation? Cell Stem Cell. 2010; 7:431–442.

3. François S, Bensidhoum M, Mouiseddine M, et al. Local irradiation not only induces homing of human mesenchymal stem cells at exposed sites but promotes their widespread engraftment to multiple organs: a study of their quantitative distribution after irradiation damage. Stem Cells. 2006; 24:1020–1029.

4. Sato Y, Araki H, Kato J, et al. Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion. Blood. 2005; 106:756–763.

5. Tanaka M, Itoh T, Tanimizu N, Miyajima A. Liver stem/progenitor cells: their characteristics and regulatory mechanisms. J Biochem. 2011; 149:231–239.

6. Manieri NA, Stappenbeck TS. Mesenchymal stem cell therapy of intestinal disease: are their effects systemic or localized? Curr Opin Gastroenterol. 2011; 27:119–124.

7. Trebol Lopez J, Georgiev Hristov T, García-Arranz M, García-Olmo D. Stem cell therapy for digestive tract diseases: current state and future perspectives. Stem Cells Dev. 2011; 20:1113–1129.

8. El-Menoufy H, Aly LA, Aziz MT, et al. The role of bone marrow-derived mesenchymal stem cells in treating formocresol induced oral ulcers in dogs. J Oral Pathol Med. 2010; 39:281–289.

9. Epperly MW, Guo H, Shen H, et al. Bone marrow origin of cells with capacity for homing and differentiation to esophageal squamous epithelium. Radiat Res. 2004; 162:233–240.

10. Sarosi G, Brown G, Jaiswal K, et al. Bone marrow progenitor cells contribute to esophageal regeneration and metaplasia in a rat model of Barrett's esophagus. Dis Esophagus. 2008; 21:43–50.

11. Fascetti-Leon F, Malerba A, Boldrin L, et al. Murine muscle pre-cursor cells survived and integrated in a cryoinjured gastroesophageal junction. J Surg Res. 2007; 143:253–259.

12. Hayashi Y, Tsuji S, Tsujii M, et al. Topical transplantation of mesenchymal stem cells accelerates gastric ulcer healing in rats. Am J Physiol Gastrointest Liver Physiol. 2008; 294:G778–786.

13. Askarov MB. Multipotent mesenchymal stromal cells from autologous bone marrow accelerate regeneration of refractory gastric ulcers. Eksp Klin Gastroenterol. 2008; (4):52–54.

14. Komori M, Tsuji S, Tsujii M, et al. Efficiency of bone marrow-derived cells in regeneration of the stomach after induction of ethanol-induced ulcers in rats. J Gastroenterol. 2005; 40:591–599.

15. Dai LJ, Li HY, Guan LX, Ritchie G, Zhou JX. The therapeutic potential of bone marrow-derived mesenchymal stem cells on hepatic cirrhosis. Stem Cell Res. 2009; 2:16–25.

16. Petersen BE, Bowen WC, Patrene KD, et al. Bone marrow as a potential source of hepatic oval cells. Science. 1999; 284:1168–1170.

17. Alison MR, Poulsom R, Jeffery R, et al. Hepatocytes from non-hepatic adult stem cells. Nature. 2000; 406:257.

18. Schwartz RE, Reyes M, Koodie L, et al. Multipotent adult progenitor cells from bone marrow differentiate into functional hep-atocyte-like cells. J Clin Invest. 2002; 109:1291–1302.

19. Yamamoto Y, Banas A, Murata S, et al. A comparative analysis of the transcriptome and signal pathways in hepatic differentiation of human adipose mesenchymal stem cells. FEBS J. 2008; 275:1260–1273.

20. Parekkadan B, van Poll D, Megeed Z, et al. Immunomodulation of activated hepatic stellate cells by mesenchymal stem cells. Biochem Biophys Res Commun. 2007; 363:247–252.

21. Wang J, Bian C, Liao L, et al. Inhibition of hepatic stellate cells proliferation by mesenchymal stem cells and the possible mechanisms. Hepatol Res. 2009; 39:1219–1228.

22. Russo FP, Alison MR, Bigger BW, et al. The bone marrow functionally contributes to liver fibrosis. Gastroenterology. 2006; 130:1807–1821.

23. van Poll D, Parekkadan B, Cho CH, et al. Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology. 2008; 47:1634–1643.

24. Jung KH, Song SU, Yi T, et al. Human bone marrow-derived clonal mesenchymal stem cells inhibit inflammation and reduce acute pancreatitis in rats. Gastroenterology. 2011; 140:998–1008.

25. Schneider G, Saur D. Mesenchymal stem cells: therapeutic potential for acute pancreatitis. Gastroenterology. 2011; 140:779–782.

26. Singh UP, Singh NP, Singh B, et al. Stem cells as potential therapeutic targets for inflammatory bowel disease. Front Biosci (Schol Ed). 2010; 2:993–1008.

27. Hayashi Y, Tsuji S, Tsujii M, et al. Topical implantation of mesenchymal stem cells has beneficial effects on healing of experimental colitis in rats. J Pharmacol Exp Ther. 2008; 326:523–531.

28. González MA, Gonzalez-Rey E, Rico L, Büscher D, Delgado M. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology. 2009; 136:978–989.

29. Zhang Q, Shi S, Liu Y, et al. Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. J Immunol. 2009; 183:7787–7798.

30. Tanaka F, Tominaga K, Ochi M, et al. Exogenous administration of mesenchymal stem cells ameliorates dextran sulfate sodium-induced colitis via anti-inflammatory action in damaged tissue in rats. Life Sci. 2008; 83:771–779.

31. Nemeth K, Leelahavanichkul A, Yuen PS, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent re-programming of host macrophages to increase their inter-leukin-10 production. Nat Med. 2009; 15:42–49.

32. Tyndall A, Pistoia V. Mesenchymal stem cells combat sepsis. Nat Med. 2009; 15:18–20.

33. Shi M, Li J, Liao L, et al. Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD/SCID mice. Haematologica. 2007; 92:897–904.

34. Ryu CH, Park SA, Kim SM, et al. Migration of human umbilical cord blood mesenchymal stem cells mediated by stromal cell-derived factor-1/CXCR4 axis via Akt, ERK, and p38 signal transduction pathways. Biochem Biophys Res Commun. 2010; 398:105–110.

35. Herrera MB, Bussolati B, Bruno S, et al. Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Int. 2007; 72:430–441.

36. Yan L, Cai C, Li J, et al. Present status and perspectives of stem cell-based therapies for gastrointestinal diseases. Stem Cell Rev. 2009; 5:278–282.

37. Jeon MS, Lim HJ, Yi TG, et al. Xenoreactivity of human clonal mesenchymal stem cells in a major histocompatibility complex- matched allogeneic graft-versus-host disease mouse model. Cell Immunol. 2010; 261:57–63.

38. Augello A, Tasso R, Negrini SM, et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol. 2005; 35:1482–1490.

39. Ren G, Su J, Zhang L, et al. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells. 2009; 27:1954–1962.